Consun Pharmaceutical Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Consun Pharmaceutical Group hat ein Gesamteigenkapital von CN¥3.9B und eine Gesamtverschuldung von CN¥503.4M, wodurch sich der Verschuldungsgrad auf 12.8% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CN¥5.5B bzw. CN¥1.6B. Consun Pharmaceutical Group Das EBIT des Unternehmens beträgt CN¥825.9M, so dass der Zinsdeckungsgrad -17.3 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CN¥3.6B.

Wichtige Informationen

12.8%

Verhältnis von Schulden zu Eigenkapital

CN¥503.42m

Verschuldung

Zinsdeckungsgrad	-17.3x
Bargeld	CN¥3.58b
Eigenkapital	CN¥3.92b
Gesamtverbindlichkeiten	CN¥1.59b
Gesamtvermögen	CN¥5.51b

Jüngste Berichte zur Finanzlage

Recent updates

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

Jun 12

Consun Pharmaceutical Group's (HKG:1681) Dividend Will Be CN¥0.30

May 12

Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30

Jun 01

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

May 04

Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20

Apr 28

Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20

Apr 07

Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10

Aug 26

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly

Apr 21

Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?

Mar 17

Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative

Feb 19

How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 29

Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?

Jan 08

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly

Dec 18

Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?

Nov 18

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 1681Die kurzfristigen Aktiva des Unternehmens (CN¥4.3B) übersteigen seine kurzfristigen Passiva (CN¥1.5B).

Langfristige Verbindlichkeiten: 1681Die kurzfristigen Vermögenswerte des Unternehmens (CN¥4.3B) übersteigen seine langfristigen Verbindlichkeiten (CN¥94.3M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 1681 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 1681 Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 15.7% auf 12.8% zurückgegangen.

Schuldendeckung: 1681Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (162.7%).

Zinsdeckung: 1681 mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.

Consun Pharmaceutical Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly

Recent updates

Consun Pharmaceutical Group Limited Announces Board and Committee Changes

Chief Scientist & Executive Director recently sold HK$8.4m worth of stock

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

New minor risk - Shareholder dilution

Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Insider recently sold HK$62m worth of stock

Consun Pharmaceutical Group Limited Announces Special Dividend, Payable on 21 June 2024

Consun Pharmaceutical Group's (HKG:1681) Dividend Will Be CN¥0.30

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consun Pharmaceutical Group Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consun Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 21 June 2024

Consun Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Consun Pharmaceutical Group Limited Announces Management Changes

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.37 in 1H 2022)

Upcoming dividend of HK$0.15 per share at 6.2% yield

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.37 in 1H 2022)

Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 20 September 2023

Consun Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 24, 2023

Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30

Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.30 per share at 6.0% yield

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.31 in 1H 2021)

Consun Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 26, 2022

Investor sentiment deteriorated over the past week

Consun Pharmaceutical Group Limited, A Wholly-Owned Subsidiary of Consun Pharmaceutical (Horgos) Co., Ltd Holds A Trial Production Ceremony in Plant No. 8, Area A05, Horgos Comprehensive Bonded Zone, Yili Kazakh

Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.20 per share

Full year 2021 earnings released: EPS: CN¥0.74 (vs CN¥0.61 in FY 2020)

Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20

Consun Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on or About 17 June 2022

Less than half of directors are independent

Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20

Investor sentiment improved over the past week

Upcoming dividend of HK$0.10 per share

Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10

First half 2021 earnings released: EPS CN¥0.31 (vs CN¥0.25 in 1H 2020)

Investor sentiment improved over the past week

Chairman of the Board Yubao An has left the company

Upcoming dividend of HK$0.20 per share

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.094 in FY 2019)

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.094 in FY 2019)

Investor sentiment improved over the past week

Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?

Consun Pharmaceutical Group Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative

How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?

New 90-day high: HK$3.40

Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly

Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?

First half earnings released

First half earnings released

New 90-day low - HK$3.02

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen